Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of "Hold" by Brokerages

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) has earned a consensus recommendation of "Hold" from the twelve ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $6.64.

Several analysts recently issued reports on the company. Craig Hallum lowered their price target on Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. UBS Group lowered their price target on Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating for the company in a report on Friday, March 21st. Robert W. Baird lowered their price target on Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Morgan Stanley lowered their price target on Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a report on Tuesday, March 25th. Finally, Stifel Nicolaus set a $5.00 price target on Maravai LifeSciences in a report on Friday, March 21st.

Institutional Trading of Maravai LifeSciences

Several large investors have recently modified their holdings of the business. 12 West Capital Management LP lifted its position in shares of Maravai LifeSciences by 8.0% during the first quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company's stock worth $27,672,000 after purchasing an additional 930,000 shares during the last quarter. Alyeska Investment Group L.P. lifted its position in shares of Maravai LifeSciences by 145.8% during the fourth quarter. Alyeska Investment Group L.P. now owns 5,329,420 shares of the company's stock worth $29,045,000 after purchasing an additional 3,161,072 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Maravai LifeSciences by 29.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,664,210 shares of the company's stock worth $25,420,000 after purchasing an additional 1,062,485 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Maravai LifeSciences by 4.9% during the fourth quarter. JPMorgan Chase & Co. now owns 4,250,656 shares of the company's stock worth $23,166,000 after purchasing an additional 200,411 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its position in shares of Maravai LifeSciences by 1.8% during the fourth quarter. Ameriprise Financial Inc. now owns 3,611,625 shares of the company's stock worth $19,683,000 after purchasing an additional 62,123 shares during the last quarter. 50.25% of the stock is currently owned by institutional investors and hedge funds.

Maravai LifeSciences Trading Up 4.5%

MRVI stock opened at $2.77 on Friday. The company has a market cap of $705.15 million, a price-to-earnings ratio of -2.43 and a beta of 0.28. The company has a quick ratio of 5.17, a current ratio of 5.96 and a debt-to-equity ratio of 0.60. The business has a fifty day simple moving average of $2.21 and a 200-day simple moving average of $3.19. Maravai LifeSciences has a 52 week low of $1.67 and a 52 week high of $10.03.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The firm had revenue of $46.85 million for the quarter, compared to analyst estimates of $44.01 million. Maravai LifeSciences had a negative return on equity of 12.91% and a negative net margin of 67.14%. The business's revenue for the quarter was down 26.9% on a year-over-year basis. On average, equities research analysts expect that Maravai LifeSciences will post -0.24 EPS for the current year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.